Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Tvardi Therapeutics to similar businesses based on the strength of its earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
Profitability
This table compares Tvardi Therapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tvardi Therapeutics | N/A | -145.40% | -91.11% |
| Tvardi Therapeutics Competitors | -2,400.61% | -215.91% | -15.58% |
Volatility & Risk
Tvardi Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics’ competitors have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.
Institutional and Insider Ownership
44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Tvardi Therapeutics and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tvardi Therapeutics | 1 | 0 | 6 | 1 | 2.88 |
| Tvardi Therapeutics Competitors | 7847 | 13801 | 25827 | 1039 | 2.41 |
Tvardi Therapeutics currently has a consensus target price of $9.40, suggesting a potential upside of 754.55%. As a group, “Pharmaceuticals” companies have a potential upside of 26.12%. Given Tvardi Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Tvardi Therapeutics is more favorable than its competitors.
Valuation & Earnings
This table compares Tvardi Therapeutics and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Tvardi Therapeutics | $7.14 million | -$18.21 million | -0.41 |
| Tvardi Therapeutics Competitors | $3.56 billion | $3.18 billion | 559.00 |
Tvardi Therapeutics’ competitors have higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Tvardi Therapeutics beats its competitors on 8 of the 13 factors compared.
Tvardi Therapeutics Company Profile
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
